
    
      Participants will be randomized in a 2:1 ratio of camostat:placebo. Approximately 300
      participants are planned to be enrolled (200 participants to camostat mesilate and 100
      participants to placebo). Participants will be treated with camostat mesilate 200 mg or
      placebo drug orally 4 times a day for 14 days, and receive local standard of care (SOC) in
      addition to study drug. Participants will be followed until Day 28. Participants will be seen
      in the clinic for assessments, blood draws, and mid-turbinate nasal samples on Screening/Day
      1, Day 7, Day 15 and early termination.
    
  